Prognosis in Hispanic patient population with pulmonary arterial hypertension: An application of common risk...

Area of Science:

• Cardiology
• Pulmonology
• Clinical Research

Background:

• Pulmonary arterial hypertension (PAH) is a cardiovascular disease with a high mortality rate.
• Current PAH treatment guidelines rely on risk stratification, validated primarily in Caucasian populations.
• Limited data exists on the applicability of these prognostic tools in Hispanic PAH patients.

Purpose of the Study:

• To evaluate the effectiveness of established risk assessment tools (COMPERA, COMPERA 2.0, REVEAL 2.0) in predicting outcomes for Hispanic patients with PAH.
• To determine if baseline risk stratification provides prognostic information in this underrepresented population.

Main Methods:

• Analysis of a single-center outpatient cohort of 135 Hispanic patients diagnosed with PAH.
• Calculation of baseline characteristics using COMPERA, COMPERA 2.0, and REVEAL 2.0 risk scores prior to PAH-targeted therapy initiation.
• Assessment of 1-year survival rates and the discriminatory ability of the risk scores.

Main Results:

• The overall 1-year survival rate for the Hispanic PAH cohort was 88%.
• The COMPERA, COMPERA 2.0, and REVEAL 2.0 risk scores demonstrated similar and reasonable discrimination of mortality across different risk strata (all p < 0.001).
• Baseline risk assessment provided significant prognostic information for this cohort.

Conclusions:

• Hispanic patients with PAH experience a high mortality rate.
• Guideline-recommended baseline risk assessment tools are valuable for predicting outcomes in Hispanic PAH patients.
• These findings support the use of established risk scores for goal-directed therapy in diverse PAH populations.